Skin Reactions from Pembrolizumab in Cervical Cancer Treatment
Author Information
Author(s): Adachi Takeya, Matsui Tomoya, Okata‐Karigane Utako, Takahashi Chiaki, Tahara Umi, Hyodo Mari, Miyagawa Akihiro, Kobayashi Kenta, Nakamura Yoshio, Funakoshi Takeru, Nishio Hiroshi, Yamagami Wataru, Takahashi Hayato
Primary Institution: Keio University School of Medicine
Hypothesis
What are the cutaneous adverse events associated with pembrolizumab combination chemotherapy in cervical cancer patients?
Conclusion
The study found that patients undergoing pembrolizumab combination chemotherapy experienced significant skin reactions, including severe cases requiring treatment adjustments.
Supporting Evidence
- The incidence of severe cutaneous adverse events was higher in combination therapies than in monotherapies.
- Four patients exhibited CTCAE grade 3 symptoms.
- Three patients experienced immediate hypersensitivity reactions during subsequent treatments.
- The study emphasizes the need for rigorous dermatological monitoring during treatment.
Takeaway
Some cancer treatments can cause skin problems, and doctors need to watch for these issues closely to keep patients safe.
Methodology
This case series retrospectively analyzed 19 female patients treated with pembrolizumab combination chemotherapy and documented their cutaneous adverse events.
Limitations
The study lacks comparative analysis and a more diverse patient cohort.
Participant Demographics
All participants were female, aged 38 to 55 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website